Technical Analysis for NKTX - Nkarta, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -1.02% | |
| Volume Surge | Other | -1.02% | |
| Wide Bands | Range Expansion | -1.02% | |
| Outside Day | Range Expansion | -0.17% | |
| Wide Bands | Range Expansion | -0.17% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.01% | |
| MACD Bullish Signal Line Cross | Bullish | -2.01% | |
| Inside Day | Range Contraction | -2.01% | |
| Wide Bands | Range Expansion | -2.01% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 8 hours ago |
| Down 2 % | about 8 hours ago |
| Up 3% | about 9 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Down 1% | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2024
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Gene Therapy Lymphoma Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Therapies For Cancer Chimeric Antigen Receptor Antigen CD19 Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Gene Therapy Lymphoma Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Therapies For Cancer Chimeric Antigen Receptor Antigen CD19 Tumor Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.24 |
| 52 Week Low | 1.28 |
| Average Volume | 819,746 |
| 200-Day Moving Average | 6.34 |
| 50-Day Moving Average | 6.55 |
| 20-Day Moving Average | 6.12 |
| 10-Day Moving Average | 5.71 |
| Average True Range | 0.48 |
| RSI (14) | 42.53 |
| ADX | 15.78 |
| +DI | 18.20 |
| -DI | 19.62 |
| Chandelier Exit (Long, 3 ATRs) | 5.95 |
| Chandelier Exit (Short, 3 ATRs) | 6.48 |
| Upper Bollinger Bands | 7.12 |
| Lower Bollinger Band | 5.12 |
| Percent B (%b) | 0.36 |
| BandWidth | 32.65 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.32 |
| MACD Histogram | 0.0419 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.35 | ||||
| Resistance 3 (R3) | 6.38 | 6.24 | 6.26 | ||
| Resistance 2 (R2) | 6.24 | 6.12 | 6.23 | 6.23 | |
| Resistance 1 (R1) | 6.05 | 6.04 | 5.98 | 6.02 | 6.21 |
| Pivot Point | 5.91 | 5.91 | 5.88 | 5.90 | 5.91 |
| Support 1 (S1) | 5.72 | 5.79 | 5.65 | 5.69 | 5.49 |
| Support 2 (S2) | 5.58 | 5.71 | 5.57 | 5.47 | |
| Support 3 (S3) | 5.39 | 5.58 | 5.44 | ||
| Support 4 (S4) | 5.36 |
